ADARx Pharmaceuticals (ADRX) vs Vir Biotechnology (VIR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Vir Biotechnology is the larger company by market cap ($1.95 billion vs $1.85 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ADRX | VIR |
|---|---|---|
| Share price | $17.33 | $11.52 |
| Market cap | $1.85B | $1.95B |
| 1-day change | -6.73% | -0.69% |
| YTD return | — | +91.04% |
| 1-year return | — | +103.53% |
| 5-year return | — | -70.53% |
| EPS (TTM) | $-1.16 | $-1.76 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $23.21 | $11.94 |
| 52-week low | $17.20 | $4.82 |
| Distance from 52-week high | -25.33% | -3.52% |
| Analyst consensus | — | strong_buy |
| Avg. price target upside | — | +80.38% |
| Average volume | 1.34M | 1.90M |
| Shares outstanding | 106.80M | 169.22M |
| Employees | 100 | 367 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About ADARx Pharmaceuticals
ADRX stock →ADARx Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on developing siRNA therapeutics to treat a broad spectrum of diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 100 employees
About Vir Biotechnology
VIR stock →Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 367 employees
ADRX vs VIR FAQ
Which is bigger, ADARx Pharmaceuticals or Vir Biotechnology?
Vir Biotechnology (VIR) is larger, with a market capitalization of $1.95B compared with $1.85B for ADARx Pharmaceuticals (ADRX).
Are ADARx Pharmaceuticals and Vir Biotechnology in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for ADARx Pharmaceuticals and Biotechnology: Biological Products (No Diagnostic Substances) for Vir Biotechnology.